SIERRA ONCOLOGY
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
SIERRA ONCOLOGY
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2004-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.sierraoncology.com
Total Employee:
101+
Status:
Active
Contact:
(604)558-6536
Email Addresses:
[email protected]
Total Funding:
494.13 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
MetronomX
MetronomX is a drug development and cancer therapeutics as well as successful entrepreneurs in marketed biologics, generics
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Sierra Oncology
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series D - Sierra Oncology
RA Capital Management
RA Capital Management investment in Series D - Sierra Oncology
Hopen Life Science Ventures
Hopen Life Science Ventures investment in Series D - Sierra Oncology
Capital Midwest Fund
Capital Midwest Fund investment in Series D - Sierra Oncology
Apjohn ventures
Apjohn ventures investment in Series D - Sierra Oncology
Vivo Capital
Vivo Capital investment in Series D - Sierra Oncology
Janus Capital Group
Janus Capital Group investment in Series D - Sierra Oncology
The Amherst Fund
The Amherst Fund investment in Series D - Sierra Oncology
OrbiMed
OrbiMed investment in Series D - Sierra Oncology
Key Employee Changes
Official Site Inspections
http://www.sierraoncology.com Semrush global rank: 4.27 M Semrush visits lastest month: 2.71 K
- Host name: 144.236.160.34.bc.googleusercontent.com
- IP address: 34.160.236.144
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Sierra Oncology"
GSK completes acquisition of Sierra Oncology
Jul 1, 2022 In June 2022, Sierra Oncology presented the complete data from the MOMENTUM phase III trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The …See details»
GSK reaches agreement to acquire late-stage biopharmaceutical …
Apr 13, 2022 About Sierra Oncology. Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat …See details»
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Apr 13, 2022 Britain's GlaxoSmithKline sought to bolster its cancer business on Wednesday by agreeing a $1.9 billion deal to buy U.S. drug developer Sierra Oncology , the latest move to …See details»
Sierra Oncology - Crunchbase Company Profile & Funding
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise …See details»
GSK acquires US-based Sierra Oncology for $1.9bn
Jul 4, 2022 The conclusion of the deal comes after the shareholders of Sierra Oncology approved the takeover on 29 June this year. Sierra develops …See details»
GSK agrees to acquire biopharma firm Sierra Oncology …
Apr 14, 2022 GlaxoSmithKline (GSK) has signed an agreement for the acquisition of US-based late-stage biopharmaceutical company Sierra Oncology for a total equity price of $1.9bn (£1.5bn), or $55 for each share, in cash. Free …See details»
GlaxoSmithKline to buy Sierra Oncology for £1.5bn to …
Apr 13, 2022 GlaxoSmithKline has reached an agreement to buy blood cancer specialist Sierra Oncology for £1.5bn as part of plans to strengthen its drug pipeline after pressure from activist investors.See details»
Sierra Oncology - LinkedIn
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds ...See details»
Sierra Oncology, Inc. - AnnualReports.com
Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib, a selective and orally-bioavailable JAK1, …See details»
GSK reaches agreement to acquire late-stage biopharmaceutical …
Apr 13, 2022 GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will …See details»
GSK completes acquisition of Sierra Oncology
Jul 4, 2022 Sierra Oncology has submitted a New Drug Application to the US Food and Drug Administration (FDA) for momelotinib and is planning regulatory submission in Europe in the second half of 2022. GSK says that the …See details»
Sierra Oncology and GlaxoSmithKline Acquisition Backstory
May 3, 2022 Sierra Oncology was ready to take momelotinib to the market, but it needed help. What started out as an effort to find a strategic partner turned into a $1.9 billion buyout from …See details»
GSK will acquire Sierra Oncology | C&EN Global Enterprise
Apr 18, 2022 GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion. Based in California, Sierra is developing momelotinib, a small-molecule drug for myelofibrosis, a fatal …See details»
GSK to Acquire Sierra Oncology for $1.9 Billion
Apr 15, 2022 GlaxoSmithKline (GSK) and Sierra Oncology, a late-stage biopharmaceutical company focused on treatments of rare forms of cancer, announced on April 13, 2022 that …See details»
Sierra Oncology Welcomes Two New Independent Directors to
Jun 3, 2021 Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to …See details»
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical ...
Jun 1, 2019 /PRNewswire/ - Sierra Oncology, Inc. ... (SRA737 potentiated by low dose gemcitabine), at the 2019 Annual Meeting of the American Society of Clinical Oncology …See details»
GSK Reaches Agreement to Acquire Late-Stage ... - Business Wire
Apr 13, 2022 About Sierra Oncology. Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat …See details»
Sierra Oncology Reports 2020 Year End Results - Newswire
Mar 11, 2021 Sierra Oncology excludes non-cash stock-based compensation expense from its non-GAAP financial measures because it believes that excluding this item provides …See details»
Sierra Oncology Welcomes Two New Independent Directors to its …
Jun 3, 2021 Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to …See details»